Tailor-made therapy for cancer based on tumor angiogenesis and hypoxia

Kruppel样因子5（KLF 5）是一种参与细胞转化、增殖和癌变的转录因子，可通过RAS突变上调。然而，关于它是作为肿瘤抑制基因还是作为癌基因的功能仍然存在争议。KLF 5在人胰腺癌细胞中的过表达不是由KRAS/Raf/MAPK/Erk信号转导介导的，而是涉及IL-1 β/IL-1 R系统、p38和转录因子HIF-1 α。KLF 5是胰腺癌治疗中一个有希望的候选靶分子。我们正在研究KLF 5在胰腺癌患者中的临床意义。

Kruppel-like factor 5(KLF5) is a transcription factor involved in cell transformation, proliferation, and carcinogenesis that can be up-regulated by RAS mutations. However, controversy persists as to whether it functions as a tumor suppressor or as an oncogene. The overexpression of KLF5 in human pancreatic cancer cells is not mediated by KRAS/Raf/MAPK/Erk signaling, but involves the IL-1beta/IL-1R system, p38, and the transcription factor HIF-1alpha. KLF5 is a promising candidate of target molecule in pancreatic cancer therapy. We are now investigating the clinical significance of KLF5 in pancreatic cancer patients.